Literature DB >> 14578506

Anti-cardiolipin antibodies in sera from patients with periodontitis.

H A Schenkein1, C R Berry, J A Burmeister, C N Brooks, S E Barbour, A M Best, J G Tew.   

Abstract

Antiphospholipid antibodies are commonly found in patients with systemic lupus erythematosus or the antiphospholipid syndrome, and a subset of such antibodies is associated with prothrombotic events such as stroke and with adverse pregnancy outcomes and fetal loss. We examined sera from 411 patients who were clinically characterized as to their periodontal disease status for serum levels of beta2-glycoprotein I-dependent anti-cardiolipin autoantibodies (anti-CL). The prevalence of patients with chronic periodontitis (CP) and generalized aggressive periodontitis (GAgP) positive for anti-CL (16.2% and 19.3%, respectively) was greater than that in healthy controls (NP) and localized aggressive periodontitis (LAgP) patients (6.8% and 3.2%). Patients with these autoantibodies demonstrated increased pocket depth and attachment loss compared with patients lacking the antibodies. Analysis of the data indicates that patients with generalized periodontitis have elevated levels of autoantibodies reactive with phospholipids. These antibodies could be involved in elevated risk for stroke, atherosclerosis, or pre-term birth in periodontitis patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14578506     DOI: 10.1177/154405910308201114

Source DB:  PubMed          Journal:  J Dent Res        ISSN: 0022-0345            Impact factor:   6.116


  24 in total

1.  Fluctuation in the Levels of Immunoglobulin M and Immunoglobulin G Antibodies for Cardiolipin and β2-Glycoprotein among Healthy Pregnant Women.

Authors:  Mohammed S Al-Balushi; Sidgi S Hasson; Elias A Said; Juma Z Al-Busaidi; Muna S Al-Daihani; Mohammed S Othman; Talal A Sallam; Mohammed A Idris; Moza Al-Kalbani; Nicholas Woodhouse; Ali A Al-Jabri
Journal:  Sultan Qaboos Univ Med J       Date:  2014-10-14

Review 2.  Inflammatory mechanisms linking periodontal diseases to cardiovascular diseases.

Authors:  Harvey A Schenkein; Bruno G Loos
Journal:  J Clin Periodontol       Date:  2013-04       Impact factor: 8.728

3.  Etiopathogenesis, clinical diagnosis and treatment of thromboangiitis obliterans - current practices.

Authors:  Edwaldo Edner Joviliano; Renata Dellalibera-Joviliano; Marcelo Dalio; Paulo Rb Evora; Carlos E Piccinato
Journal:  Int J Angiol       Date:  2009

4.  [Research progress on the relationship and mechanisms between periodontal disease and preterm birth and low-birth-weight infants].

Authors:  Wu Wanhong; Ye Changchang; Huang Ping
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2017-10-01

5.  Lipoproteins and lipoprotein metabolism in periodontal disease.

Authors:  Rachel Griffiths; Suzanne Barbour
Journal:  Clin Lipidol       Date:  2010-06

6.  Anticardiolipin in porphyromonas gingivalis antisera causes fetal loss in mice.

Authors:  H A Schenkein; J L Bradley; D B Purkall
Journal:  J Dent Res       Date:  2013-07-15       Impact factor: 6.116

Review 7.  Periodontitis: from microbial immune subversion to systemic inflammation.

Authors:  George Hajishengallis
Journal:  Nat Rev Immunol       Date:  2015-01       Impact factor: 53.106

8.  Evaluation of serum anti-cardiolipin antibodies after non-surgical periodontal treatment in chronic periodontitis patients.

Authors:  Farin Kiany; Azita Hedayati
Journal:  Odontology       Date:  2014-02-14       Impact factor: 2.634

9.  Periodontitis as a risk factor for cardiovascular disease: the role of anti-phosphorylcholine and anti-cardiolipin antibodies.

Authors:  K Karnoutsos; P Papastergiou; S Stefanidis; A Vakaloudi
Journal:  Hippokratia       Date:  2008-07       Impact factor: 0.471

10.  Anti-cardiolipin from periodontitis patients induces MCP-1 production by human umbilical vein endothelial cells.

Authors:  Harvey A Schenkein; Robert Sabatini; Thomas E Koertge; Carol N Brooks; Donald B Purkall
Journal:  J Clin Periodontol       Date:  2013-01-02       Impact factor: 8.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.